JPET Fast Forward. Published on November 10, 2005 as DOI: 10.1124/jpet.105.094508 JPET FastThis Forward. article has not Published been copyedited on andNovember formatted. The 10, final 2005 version as mayDOI:10.1124/jpet.105.094508 differ from this version. JPET #94508 Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration and Salivary Secretion Downloaded from TOMOMI OKI, AYAKO TOMA-OKURA & SHIZUO YAMADA jpet.aspetjournals.org at ASPET Journals on October 9, 2021 Department of Pharmacokinetics and Pharmacodynamics and Center of Excellence Program in the 21st Century, School of Pharmaceutical Sciences, University of Shizuoka (TO, AO, SY), Shizuoka, Japan. 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on November 10, 2005 as DOI: 10.1124/jpet.105.094508 This article has not been copyedited and formatted. The final version may differ from this version. JPET #94508 A running title : Advantages of Transdermal over Oral Oxybutynin Correspondence to: Shizuo Yamada, Ph.D., Department of Pharmacokinetics and Pharmacodynamics and Center of Excellence Program in the 21st Century, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan. (Tel: +81-54-264-5631, Fax: +81-54-264-5635, E-mail:
[email protected]) Downloaded from Text pages: 23 pages (title page to reference page) Tables : 4 Figures: 6 jpet.aspetjournals.org References: 34 Abstract: 248 words Introduction: 433 words at ASPET Journals on October 9, 2021 Discussion: 1486 words ABBREVIATIONS: [3H]NMS: [N-methyl-3H]scopolamine methyl chloride, DEOB: N-desethyl-oxybutynin, Kd: apparent dissociation constant, Bmax: maximum number of binding sites Recommended section: Neuropharmacology 2 JPET Fast Forward.